Undisclosed TPIM™ Programs

About Redesign Science

Redesign Science is a private, pre-clinical stage biotech company pioneering a dynamic structure-based drug discovery approach. Its core technology, the NUVO™ platform, uniquely integrates enhanced sampling molecular dynamics (physics) with generative AI (chemistry) and machine learning on synthetic data to model protein motion, discover novel binding pockets, and design optimized drug candidates. The company is advancing an internal pipeline of first-in-class small molecules aimed at modulating protein-protein interactions, targeting complex diseases in oncology and autoimmune indications where traditional methods have struggled. Redesign Science operates as a therapeutics company, indicating a focus on developing and commercializing its own drugs rather than providing a pure technology service.

Therapeutic Areas

Other Oncology and Autoimmune diseases Drugs